Posted

July 24, 2021

Heartbeat Medical closes Series A financing round with a volume of 5 million euros

Press Release, 05.10.2020

  • btov Partners, HV Holtzbrinck Ventures and HTGF invest in patient-centred healthcare
  • New standards for care management are set by connecting and utilising clinical data alongside data tracking patient-provided perspectives on their health status over time
  • Fundamental trend in health care: Patient-Reported Outcome Measures (PROMS) and Real World Evidence (RWE)
  • Over 200 hospital teams, registries and research institutions have registered to use the platform registered as a CE-marked medical device
Moritz Neubauer
Communications Manager

Berlin, 05 October 2020. The digital health start-up heartbeat medical has closed a Series A financing round with a volume of 5 million euros. The funds will be used to support organisational development and the expansion of capabilities of skills in the field of data analysis.

There is a great need for better data in quality assurance, measurement of treatment outcomes and medical research. This is where heartbeat medical steps in with its novel digital solutions. With its software, the start-up makes it possible for longitudinal patient-reported data to play an important role in their care management.

For the first time, Patient-Reported Outcome Measures (PROMs) are systematically linked to clinical data to improve treatment and research. In this way, clinical and scientific knowledge can be gained from routine clinical data (Real World Evidence, RWE). Scientifically well-founded and developed together with medical staff, heartbeat medical enables numerous medical departments to better manage care as well as to evaluate products and therapies using Real World Evidence.

The financing round is led by new investor btov Partners and existing investor HV Holtzbrinck Ventures. In addition, High-Tech Gründerfonds (HTGF) is increasing its holdings. After successful establishment in the German market and several years of proof of feasibility in regular clinical operation, heartbeat medical is aiming to expand the market leadership of its platform, classified as a medical device, in care management through PROMs.

In addition, the investment is to be used to further develop the current range of services. At present, more than 200 departments, registries and research projects are already under contract, which has enabled more than 150,000 patients to receive comprehensive support in their treatment. While these patients particularly benefit from the intuitive and personalised user interface, the medical staff is supported by a high degree of automation and intuitive data presentation.

“The health care system is experiencing a fundamental change in terms of how we understand the success of treatment,“ says Yannik Schreckenberger, managing director of heartbeat medical. “The improvements in the quality of life actually felt by patients through conservative, surgical and drug treatments are becoming comparable to purely clinical data as a basis for decision-making. Reliably collected, representative and high-quality health data are the basis for subsequent innovations and improvements.“

Jan-Hendrik Bürk, Principal at btov, says: “With its data-driven approach, heartbeat has the best chance of becoming a central provider for improvements in clinical treatments and processes as well as drug development. In doing so, heartbeat medical benefits from global regulatory developments that accelerate patient-centered healthcare.“

Download full press release: Press release: 5 million euros investment in heartbeat medical (EN)

Download press kit: Heartbeat Medical Overview (EN)

Management